Following the initial close in November 2021 and the successful closing of four projects, CBC HIP continues to generate substantial pipeline, and the inclusion of Mubadala as an investor allows CLSRA Venture I to secure further opportunities. The life science real assets sector is a vital part of China's new economic landscape and continues to benefit from significant tailwinds.

Fu Wei, Chief Executive Officer of CBC Group, said, “We are very pleased to welcome Mubadala as an investor in CLSRA Venture I. The strong interest we have seen from leading institutional investors is a clear market validation of our strategy, and endorsement of the sector’s opportunity for further growth. CBC Group has established a strong ecosystem for the creation of strategic value and synergies for life science clients across our CBC HIP platform.”

Matthias Neuling, Head of Asia & DACH, Real Estate at Mubadala, added, “We have great confidence in the growth potential of China’s life science real assets sector, which benefits from strong market fundamentals, demographic trends, and government support. We are excited to be joining CBC HIP and APG and look forward to help building China’s foremost portfolio of best-in-class life science real assets.”

CBC HIP has been proactive in transforming raised capital into impactful investments. The CLSRA Venture I has committed and deployed US$450 million — or 90% of the capital secured during the first close — across four real estate projects. In July 2023, CLSRA Venture I expanded its footprint into Suzhou, a top-three life science city in China (alongside Beijing and Shanghai), by acquiring a 58-mu piece of greenfield land named Project Center. Project Center sits within LifeBAY, a rapidly growing life science cluster with proximity to BioBAY, one of the top-three life science clusters in China. With a total GFA of 113,374 sqm, Project Center is positioned to provide best-in-class integrated life science facilities with flexibility to accommodate both R&D and manufacturing demand from life science companies. Since the establishment of CLSRA Venture I in November 2021, it has acquired approximately 520,000 sqm life science real assets in Shanghai, Beijing, and Suzhou, top three life science cities in China, with steady risk-adjusted returns for long term institutional investors.

Hans Kang, Chief Executive Officer of CBC HIP, concluded, “Together with like-minded partners, we will continue to tap the immense potential of life science real assets as a critical component of China's growing healthcare and life science industry, and empower life science companies to provide quality but affordable healthcare products and services for the largest aging population in the world.”